X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
Listed Suppliers
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
Details:
Under the terms of the agreement, Wistar grants Active Biotech a global exclusive license to develop and commercialize tasquinimod in combination therapy, as a treatment for multiple myeloma.
Lead Product(s): Tasquinimod,Ixazomib Citrate,Lenalidomide
Therapeutic Area: Oncology Product Name: ABR-215050
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Active Biotech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition May 22, 2024
Details:
Ninlaro® (ixazomib) is the first and only oral proteasome inhibitor licensed in combination with lenalidomide and dexamethasone for adults with multiple myeloma (MM).
Lead Product(s): Ixazomib Citrate,Lenalidomide,Dexamethasone
Therapeutic Area: Oncology Product Name: Ninlaro
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2023
Details:
Tasquinimod is an oral immunomodulatory and anti-angiogenic investigational treatment, that affects the tumor’s ability to grow and metastasize. Tasquinimod is developed as a new immunomodulatory treatment for multiple myeloma.
Lead Product(s): Tasquinimod,Ixazomib Citrate,Lenalidomide
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 03, 2021
Details:
Ninlaro (ixazomib) is an oral proteasome inhibitor, small molecule drug candidate which is being evaluated for the treatment of patients with multiple myeloma.
Lead Product(s): Ixazomib Citrate,Lenalidomide,Dexamethasone
Therapeutic Area: Oncology Product Name: Ninlaro
Highest Development Status: Phase IIIProduct Type:
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 09, 2020
Details:
Positive Phase 3 Data Evaluating NINLARO as a Maintenance Therapy (TOURMALINE-MM4) Shows Significant Improvement in Progression-Free Survival in Adult Patients Not Treated with Stem Cell Transplantation.
Lead Product(s): Ixazomib Citrate,Lenalidomide,Dexamethasone
Therapeutic Area: Oncology Product Name: Ninlaro
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2020
Details:
TOURMALINE-MM4, a Phase 3, randomized clinical trial evaluating the effect of single-agent oral NINLARO™ (ixazomib), an oral proteasome inhibitor used as a first-line maintenance therapy in adult patients diagnosed with multiple myeloma.
Lead Product(s): Ixazomib Citrate,Lenalidomide,Dexamethasone
Therapeutic Area: Oncology Product Name: Ninlaro
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2020
Details:
The addition of ixazomib to lenalidomide and dexamethasone resulted in an improvement in median progression-free survival of 13.5 months; however, it did not meet the statistical significance.
Lead Product(s): Ixazomib Citrate,Lenalidomide,Dexamethasone
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 10, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
